

Resource Summary Report

Generated by [NIF](#) on Sep 8, 2026

DMS 114

RRID:CVCL_1174

Type: Cell Line

Proper Citation

RRID:CVCL_1174

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1174

Proper Citation: RRID:CVCL_1174

Description: Cell line DMS 114 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Thoracic SMARCA4-deficient undifferentiated tumor

Defining Citation: [PMID:2041050](#), [PMID:2388294](#), [PMID:2986244](#), [PMID:3335022](#), [PMID:6266631](#), [PMID:7718330](#), [PMID:9212023](#), [PMID:9744504](#), [PMID:12712436](#), [PMID:15900046](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22336246](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:27247353](#), [PMID:27397505](#), [PMID:28766886](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32586373](#), [PMID:35839778](#), [PMID:38180245](#)

Comments: Caution: Originally classified as originating from a lung small cell carcinoma, but is reclassified as a thoracic SMARCA4-deficient undifferentiated tumor based on a number of criteria (PubMed=38180245)., Population: Caucasian., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: FGFR genetic alteration cell panel (ATCC TCP-1034)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: DMS 114

Synonyms: DMS-114, DMS114, Darmouth Medical School 114

Cross References: BTO:BTO_0004813, CLO:CLO_0002795, EFO:EFO_0002162, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770,

ArrayExpress:E-MTAB-3610, ATCC:CRL-2066, BioGRID_ORCS_Cell_line:805, BioSample:SAMN03471429, BioSample:SAMN10988190, cancercellines:CVCL_1174, Cell_Model_Passport:SIDM00865, ChEMBL-Cells:ChEMBL3307670, ChEMBL-Targets:ChEMBL614642, CLS:305364, Cosmic:687983, Cosmic:1436016, Cosmic:2125177, Cosmic:2648005, Cosmic-CLP:687983, DepMap:ACH-000530, EGA:EGAS00001000978, FANTOM5_SSTAR:10841-111E4, GDSC:687983, GEO:GSM784211, GEO:GSM886980, GEO:GSM888049, GEO:GSM1374464, GEO:GSM1374465, GEO:GSM1374466, GEO:GSM1669735, GEO:GSM1887902, GEO:GSM1887985, IARC_TP53:21305, IARC_TP53:21640, IGRhCellID:DMS114, LiGeA:CCLE_413, LINCS_LDP:LCL-1830, NCI-DTP:DMS-114, PharmacDB:DMS114_297_2019, PRIDE:PXD011896, PRIDE:PXD030304, Progenetix:CVCL_1174, PubChem_Cell_line:CVCL_1174, Wikidata:Q54831291

ID: CVCL_1174

Record Creation Time: 20220427T215820+0000

Record Last Update: 20260905T175235+0000

Ratings and Alerts

No rating or validation information has been found for DMS 114.

No alerts have been found for DMS 114.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Dutta Chowdhury D, et al. (2026) TNIK overexpression is sufficient for chemoradiation resistance in limited-stage small cell lung cancer. Molecular cancer therapeutics.

Kostas M, et al. (2026) Unconventional activation of the proto-oncogene FGFR1 by extracellular phosphate via H2O2-mediated kinase oxidation. Cell reports, 45(6), 117504.

Ahmad T, et al. (2026) KDM7B-mediated demethylation of RNF113A regulates small cell lung cancer sensitivity to alkylation damage. bioRxiv : the preprint server for biology.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. Cancer research communications, 5(1), 24.

Panda PK, et al. (2025) BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(7), 1333.

Hsu CC, et al. (2024) Exosomal Thomsen-Friedenreich Glycoantigen: A New Liquid Biopsy Biomarker for Lung and Breast Cancer Diagnoses. *Cancer research communications*, 4(8), 1933.

Chakraborty S, et al. (2024) Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. *Cell reports. Medicine*, 5(12), 101852.

Ng J, et al. (2024) Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. *Clinical cancer research : an official journal of the American Association for Cancer Research*, OF1.

Liu Q, et al. (2024) Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. *Cell*, 187(1), 184.

Dexheimer TS, et al. (2023) Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs. *Cancer research communications*, 3(8), 1648.

Lukinovi?? V, et al. (2022) SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk. *Cancer discovery*, 12(9), 2158.

Taniguchi H, et al. (2022) WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. *Cell reports*, 39(7), 110814.

Yang H, et al. (2021) Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer. *EBioMedicine*, 69, 103457.

Pecere T, et al. (2021) On the mechanism of tumor cell entry of aloe-emodin, a natural compound endowed with anticancer activity. *International journal of cancer*, 149(5), 1129.

Thomas A, et al. (2021) Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. *Cancer cell*, 39(4), 566.

Cao Z, et al. (2021) ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. *Molecular cell*, 81(17), 3604.

Englinger B, et al. (2020) Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib. *International journal of cancer*, 147(6), 1680.

Tarumoto Y, et al. (2018) LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. *Molecular cell*, 69(6), 1017.

Jin L, et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. *Cancer cell*, 34(2), 315.

Shirole NH, et al. (2016) TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions. *eLife*, 5.